Breast cancer is the most commonly diagnosed cancer among U.S. women and is the second leading cause of cancer-related mortality. A woman’s lifetime risk for developing breast cancer, assuming she lives at least 80 years, is 12.5 percent (1 out of 8). The last decade has seen a striking decrease in the overall mortality rate of this disease. While advances in treatment of breast cancer have certainly contributed to this decline, increased screening and prevention strategies have definitely played a vital role as well.

This year, more than 200,000 women in the United States will be diagnosed as having invasive breast cancer. Family physicians are often the first contact for women concerned about their breast health and information on the latest screening and disease prevention is essential for the primary care provider.

Presented by:
Robin Marie Ciocca, DO
Attending Surgeon, Department of General Surgery
The Lankenau Hospital
Philadelphia, Pennsylvania

Upon completion of the CME activity, participants should be able to:

• Conduct the steps to assess breast cancer risk for individual patients.
• Identify patients for whom breast cancer risk reduction is feasible.
• Be aware of the reduction in breast cancer risk in older women being treated for osteoporosis and Selective Estrogen Receptor Modulators
  
• and to analyze the risks and benefits of Selective Estrogen Receptor Modulators in breast cancer prevention.

An Expert Panel met to develop this evidence-based enduring material on health issues related to predicting and preventing breast cancer.  It includes a discussion of the barriers to optimal prevention strategies, the benefits and risks of accepted breast cancer prevention treatments, and the shared decision-making processes with patients for optimal prevention plans.  This panel reviewed the established guidelines, the current medical literature, and their own clinical experiences to formulate a consensus recommendation for family physicians regarding Breast Cancer Prevention.  
 
This activity has been peer reviewed and is acceptable for three (3) Prescribed credits by the AAFP.  The Prescribed credits conform to the AAFP criteria for evidence-based CME clinical content and is equivalent to 3 Category 2-A AOA credit hours.

The ACOFP is accredited by the American Osteopathic Association to sponsor continuing medical education for osteopathic physicians. The ACOFP designates the podcast for Category 1-B credit on an hour-for-hour basis.

This program is supported by an educational grant from Lilly USA, LLC.

Dr. Robin M. Ciocca has reported no devise or drug company affiliations that could represent potential conflicts of interest.  This program does not include any discussion or demonstrate any pharmaceuticals or medical devices that are not approved by the FDA, or are considered “off-labeled”.

This program is sponsored by the ACOFP for educational purposes only. The material presented is not intended to represent the only or the best methods appropriate for the medical situations discussed, but rather, are intended to present the opinions of the authors or presenters that may be helpful to other practitioners. Attendees participating in this medical education program sponsored by the ACOFP do so with full knowledge that they waive any claim they may have against the ACOFP for reliance on any information presented during these educational activities.